What is Bayer’s position on genetic engineering?
We are keen to explore the potential of genetic technology, especially as a method of producing new medicines and improving seed.
For example, the company has successfully used genetic engineering to develop drugs for the treatment of multiple sclerosis, hemophilia and certain eye diseases. Genetic engineering in the development of pharmaceutical products, or “red” genetic engineering as it is known, is widely accepted.
However, “green” genetic engineering, i.e. genetic engineering in agriculture, is rejected by the majority of people and politicians in Europe, even though there is no scientific justification for doing so. Not one scientifically tenable study has ever indicated any risk to health posed by the use of genetic engineering in crop breeding per se.
Genetic engineering offers farmers a number of concrete advantages already today. Genetically engineered seeds help them produce higher harvests from the same amount of resources. We primarily use genetic engineering to breed soy, cotton and rapeseed seeds.
Safety is our top priority when it comes to the application of genetic engineering as well. We naturally comply with all applicable laws and regulations and the industry standards, and have also established our own additional internal rules.